Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50


Efficacy and safety of proton pump inhibitors for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis of randomized trials.

Alshamsi F, Belley-Cote E, Cook D, Almenawer SA, Alqahtani Z, Perri D, Thabane L, Al-Omari A, Lewis K, Guyatt G, Alhazzani W.

Crit Care. 2016 May 4;20(1):120. doi: 10.1186/s13054-016-1305-6.


Stress ulcer prophylaxis with a proton pump inhibitor versus placebo in critically ill patients (SUP-ICU trial): study protocol for a randomised controlled trial.

Krag M, Perner A, Wetterslev J, Wise MP, Borthwick M, Bendel S, Pelosi P, Keus F, Guttormsen AB, Schefold JC, Møller MH; SUP-ICU investigators.

Trials. 2016 Apr 19;17(1):205. doi: 10.1186/s13063-016-1331-3.


Inhibition of Gastric Acid Secretion by H2 Receptor Antagonists Associates a Definite Risk of Enteric Peritonitis and Infectious Mortality in Patients Treated with Peritoneal Dialysis.

Pérez-Fontan M, Machado Lopes D, García Enríquez A, López-Calviño B, López-Muñiz A, García Falcón T, Rodríguez-Carmona A.

PLoS One. 2016 Feb 12;11(2):e0148806. doi: 10.1371/journal.pone.0148806. eCollection 2016.


Proton pump inhibitors alter the composition of the gut microbiota.

Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ.

Gut. 2016 May;65(5):749-56. doi: 10.1136/gutjnl-2015-310861. Epub 2015 Dec 30. Erratum in: Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):188.


Proton pump inhibitors affect the gut microbiome.

Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A.

Gut. 2016 May;65(5):740-8. doi: 10.1136/gutjnl-2015-310376. Epub 2015 Dec 9.


Etiology and Risk Factors of Acute Gastroenteritis in a Taipei Emergency Department: Clinical Features for Bacterial Gastroenteritis.

Lai CC, Ji DD, Wu FT, Mu JJ, Yang JR, Jiang DD, Lin WY, Chen WT, Yen MY, Wu HS, Chen TH.

J Epidemiol. 2016;26(4):216-23. doi: 10.2188/jea.JE20150061. Epub 2015 Dec 5.


Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs.

Benmassaoud A, McDonald EG, Lee TC.

CMAJ. 2016 Jun 14;188(9):657-62. doi: 10.1503/cmaj.150570. Epub 2015 Nov 23. Review. No abstract available.


Mechanisms and therapeutic effectiveness of lactobacilli.

Di Cerbo A, Palmieri B, Aponte M, Morales-Medina JC, Iannitti T.

J Clin Pathol. 2016 Mar;69(3):187-203. doi: 10.1136/jclinpath-2015-202976. Epub 2015 Nov 17. Review.


Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea.

Weiss K, Louie T, Miller MA, Mullane K, Crook DW, Gorbach SL.

BMJ Open Gastroenterol. 2015 Mar 2;2(1):e000028. doi: 10.1136/bmjgast-2014-000028. eCollection 2015.


C. difficile Infection: Changing Epidemiology and Management Paradigms.

Vindigni SM, Surawicz CM.

Clin Transl Gastroenterol. 2015 Jul 9;6:e99. doi: 10.1038/ctg.2015.24.


Implication of gut microbiota in nonalcoholic fatty liver disease.

Boursier J, Diehl AM.

PLoS Pathog. 2015 Jan 27;11(1):e1004559. doi: 10.1371/journal.ppat.1004559. eCollection 2015 Jan. No abstract available.


Probiotics for antibiotic-associated diarrhea: do we have a verdict?

Issa I, Moucari R.

World J Gastroenterol. 2014 Dec 21;20(47):17788-95. doi: 10.3748/wjg.v20.i47.17788. Review.


Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients.

Barletta JF, Sclar DA.

Crit Care. 2014 Dec 24;18(6):714. doi: 10.1186/s13054-014-0714-7.


Proton pump inhibitors and hospitalization with hypomagnesemia: a population-based case-control study.

Zipursky J, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Paterson JM, Lathia N, Juurlink DN.

PLoS Med. 2014 Sep 30;11(9):e1001736. doi: 10.1371/journal.pmed.1001736. eCollection 2014 Sep.


Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites.

Ratelle M, Perreault S, Villeneuve JP, Tremblay L.

Can J Gastroenterol Hepatol. 2014 Jun;28(6):330-4.


Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

Durand C, Willett KC, Desilets AR.

Clin Med Insights Gastroenterol. 2012 Oct 15;5:65-76. doi: 10.4137/CGast.S9588. eCollection 2012. Review.


Proton pump inhibitor use before percutaneous endoscopic gastrostomy is associated with adverse outcomes.

Im JP, Cha JM, Kim JW, Kim SE, Ryu DY, Kim EY, Kim ER, Chang DK.

Gut Liver. 2014 May;8(3):248-53. doi: 10.5009/gnl.2014.8.3.248.


Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Iv EC, Iii EC, Johnson DA.

World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):1-26. doi: 10.4292/wjgpt.v5.i1.1. Review.


Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection.

Vincent C, Stephens DA, Loo VG, Edens TJ, Behr MA, Dewar K, Manges AR.

Microbiome. 2013 Jun 28;1(1):18. doi: 10.1186/2049-2618-1-18.


Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole.

Tang RS, Wu JC.

Clin Interv Aging. 2013;8:1433-43. doi: 10.2147/CIA.S41350. Epub 2013 Oct 25. Review.

Items per page

Supplemental Content

Write to the Help Desk